Propensity score methods are widely used in comparative effectiveness research using claims data. In this context, the inaccuracy of procedural or billing codes in claims data frequently misclassifies patients into treatment groups, that is, the treatment assignment (T ) is often measured with error. In the context of a validation data where treatment assignment is accurate, we show that misclassification of treatment assignment can impact three distinct stages of a propensity score analysis: (i) propensity score estimation; (ii) propensity score implementation; and (iii) outcome analysis conducted conditional on the estimated propensity score and its implementation. We examine how the error in T impacts each stage in the context of three common propensity score implementations: subclassification, matching, and inverse probability of treatment weighting (IPTW). Using validation data, we propose a two-step likelihood-based approach which fully adjusts for treatment misclassification bias under subclassification. This approach relies on two common measurement error-assumptions; non-differential measurement error and transportability of the measurement error model. We use simulation studies to assess the performance of the adjustment under subclassification, and also investigate the method's performance under matching or IPTW. We apply the methods to Medicare Part A hospital claims data to estimate the effect of resection versus biopsy on 1-year mortality among 10 284 Medicare beneficiaries diagnosed with brain tumors. The ICD9 billing codes from Medicare Part A inaccurately reflect surgical treatment, but SEER-Medicare validation data are available with more accurate information.
INTRODUCTION
When comparing the effectiveness of treatment strategies as they are employed in routine practice, observational studies are often the only feasible option but have limitations. Absent the benefits of randomization, 696 D. BRAUN AND OTHERS differences in patient characteristics may confound treatment comparisons. Propensity score methods have gained widespread use for confounding adjustment in these settings (Rosenbaum and Rubin, 1983) .
Propensity score analysis consists of three sequential stages (Harder and others, 2010) . The first stage, the propensity score estimation, estimates the propensity score by modeling the treatment assignment conditional on the available covariates. Conditional on the estimated propensity score, the second stage, the propensity score implementation, creates groups or pseudopopulations of observations where treatment groups have similar values of the estimated propensity score. In this work, we consider three common implementations: subclassification, matching, and inverse probability of treatment weighting (IPTW). In the third stage, the outcome analysis, outcomes are compared among treated and untreated observations within groups or pseudopopulations constructed in the implementation stage.
All three stages of propensity score analysis rely on an accurate measure of treatment assignment, presenting challenges to the analysis of administrative data sources (e.g., claims data) where treatment assignment is often measured with error (Whittle and others, 1991; Du and others, 1999) . Existing measurement-error literature has considered mismeasured treatment in the context of regression models, including likelihood-based approaches, regression calibration, SIMEX, and Bayesian approaches (Thomas and others, 1993; Cook and Stefanski, 1994; Carroll and others, 2006) . Other methods to adjust for error in outcome variables have relevance to propensity score estimation, when treatment assignment, T , is considered as the outcome (Pepe, 1992; Buonaccorsi, 1996; Paulino and others, 2003) . However, these methods cannot be directly applied when estimating causal effects with propensity scores because of the sequential nature of the three propensity score stages. For example, measurement error in T will directly impact the propensity score estimation stage and result in error-prone propensity score estimates. Implementing these estimates will propagate the measurement error into the implementation stage, and conducting the outcome analysis conditional on this implementation will suffer further from the mismeasured T (see Figure 1 ). In addition to this sequential propagation of the measurement error, we illustrate the essential feature that measurement error in T can also independently impact all three analysis stages. Thus, adjusting for measurement error in any one of the three stages may not completely account for measurement error in the other stages. This is in contrast to existing literature on propensity score estimation with mismeasured covariates, where successful measurement error adjustment in the propensity score estimation stage can avert the need for further adjustment in subsequent stages (Stürmer and others, 2005; McCaffrey and others, 2013; Webb-Vargas and others, 2015; Steiner and others, 2011) . Measurement error in T has been considered in a propensity score context by Babanezhad and others (2010) , who derived asymptotic bias expressions for IPTW and doubly robust estimators. They do not distinguish the role of the measurement error in each of the three stages of the analysis. To our knowledge, a framework to correct for error in the treatment within a propensity score analysis that deals with the complexity of the error across the three stages is lacking.
By considering these three stages of propensity score analysis in sequence, we show that measurement error in T always impacts the propensity score estimation stage and the outcome analysis stage, but that it may or may not impact the implementation stage depending on how the propensity score is used (see Figure 1 ). For the common implementation where observations are stratified into subclasses based on quantiles of the estimated propensity score, we will demonstrate that error in T does not impact the implementation stage. For this implementation, we propose a two-step likelihood-based approach, where the first step adjusts for the error in the estimation of the propensity score and the second step adjusts for the error in the outcome model. Using validation data with both the true and mismeasured treatment, this approach completely adjusts for the measurement error in T . In contrast, error in T affects the implementation stages for both matching and IPTW. This occurs because the true treatment status is required both to match treated and untreated observations and to define weights for IPTW. While the proposed two-step likelihood adjustment does not fully adjust for measurement error in (2) Fig. 1 . Error in the treatment assignment (T) will always directly influence the propensity score estimation and outcome analysis, and will "sometimes" directly influence the propensity score implementation as well. In contrast, error in the confounders (X) will only influence the propensity score estimation.
these implementations, we investigate the relative robustness of mismeasured T for these implementations as well, and characterize the circumstances that are most susceptible to the impacts of mismeasured T .
We illustrate our approach with a comparative effectiveness study of surgical treatments (resection versus biopsy) on mortality among 42 875 elderly individuals (aged 65 or older) diagnosed with malignant neoplasm of brain (brain tumor) between 1999 and 2007. Medicare Part A hospital claims data are representative of the population of interest, but have treatment information available from ICD9 billing codes (T ep ), which are an inaccurate measure of the actual procedure performed on the patient. Data on a subset of 4729 individuals are available from SEER-Medicare, a cancer surveillance database with more detailed information. The SEER-Medicare is our internal validation data, but it is not a representative sample of the Medicare Part A population with differing distributions of the treatment, confounders, and outcomes. Therefore, the average treatment effect (ATE) cannot be estimated directly in SEER-Medicare, and we apply our proposed adjustment. Preliminary analyses based on this SEER-Medicare indicate that the majority of the patients that had a resection according to SEER procedural codes were billed as such according to ICD9 codes (sensitivity, P(T ep = 1|T = 1): 96.8%), but patients with SEER procedural codes indicating a biopsy often have ICD9 codes indicating resection (specificity, P(T ep = 0|T = 0): 26.2%).
GENERAL NOTATION AND TARGET ESTIMAND

Notation
Let Y denote the true outcome (e.g. binary disease status which is the focus of this work, or a continuous, categorical, or survival outcome, for which our method extends), T denote a true binary treatment equaling 1 or 0 (e.g. resection or biopsy based on SEER procedural codes), T ep denote the error-prone binary treatment (e.g. resection or biopsy based on ICD9 billing codes from Medicare Part A), and X denote a vector of observed potential confounders measured without error (e.g. age, co-morbidity, etc). Let i = 1, ..., N m index individuals in the main study (e.g. Medicare Part A claims). For these individuals, only Y , T ep and X are available. In addition, suppose a validation study (e.g. SEER-Medicare) that collects data on T , T ep , X, and Y with j = 1, ..., N v individuals, where typically N v < N m . We assume that the observations are independent.
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Target estimand
The target estimand is the average treatment effect (
, where Y 0 is the outcome an individual would have had if he/she were untreated, and Y 1 is the outcome an individual would have had if he/she were treated. The observed outcome, Y , is defined as Y = TY 1 + (1 − T )Y 0 . The causal effect can be estimated from the observed data provided that (i) (T , Y , X) are measured without error, (ii) each individual has a positive probability of being either treated or untreated: 0 < P(T = 1|X) < 1 for all X, (iii) the treatment assignment is ignorable, so that, conditional on X, the potential outcomes are independent of T : (Y 0 , Y 1 ) ⊥ T |X. Under these assumptions, propensity scores can be used to estimate with observed-data comparisons among treated and untreated observations with similar covariate profiles. Settings with treatment misclassification present a challenge since T ep is observed instead of T , and therefore it is unknown as whether any given observed value of Y represents Y 0 or Y 1 .
Our goal is the estimation of ATE that is fully adjusted for error in T . We accomplish this by introducing a likelihood for the observed outcomes conditional on propensity score estimation and implementation (Section 3.3). The likelihood is written differently for each propensity score implementation considered (Section 4).
IMPACT OF MISCLASSIFIED T ON THE THREE STAGES OF THE ANALYSIS
Propensity score estimation
To model the true propensity score, we consider a generalized linear model (GLM) relating
, where g is known. We consider this the goldstandard propensity score, which could be estimated directly if T were known in the main study. Absent information on the true T in the main study, an analogous error-prone propensity score can be modeled with:
. Propensity score estimates derived from these models will be denoted with PS true and PS ep respectively. Misclassified T has a direct impact on the propensity score estimation stage, as PS ep is a biased estimate of PS true .
Propensity score implementation
In this article, we consider three ways in which the propensity score can be implemented, all conditional on the estimated propensity score. Note that while the propensity score estimation stage (and outcome stage, discussed in Section 3.3) can be represented with a likelihood expression, the implementation stage represents a decision process for constructing groups of comparable observations with respect to the estimated propensity score, and is not, strictly speaking, part of a data-generating likelihood.
3.2.1. Subclassification Consider classifying individuals into K groups, each group containing N k observations having similar values of the estimated propensity score. Assuming that the propensity score were estimated in a manner that perfectly accounts for misclassified T , various approaches can be used to form the K subgroups which may or may not involve T directly. For example, subclassifying observations based on propensity score quantiles to create equal sized subgroups does not involve knowledge of which observations are treated or untreated. Forming subclasses to ensure a certain ratio of treated:control units would. We focus on subclassification based on propensity score quantiles, which does not require an indicator of treatment assignment, and thus the misclassified T does not directly impact the implementation stage.
3.2.2. Matching Matching implementation involves matching treated individuals to untreated individuals based on estimated propensity scores, which unlike subclassification, necessarily relies on knowing the treatment assignment. Regardless of how the propensity score estimation is carried out, this stage will be subject to measurement error. In other words, even if the propensity score were estimated in a manner that perfectly accounts for misclassified T , the estimators would still suffer from error due to the reliance on the treatment indicator in the implementation. There are many matching procedures, we focus on full matching as implemented in the MatchIt R-Package (Ho and others, 2011; Stuart and Green, 2008) . This procedure uses all treated and untreated observations and can thus be thought of as an extension of subclassification where a higher number of subclasses are formed using an indicator of treatment assignment (Stuart, 2010) .
3.2.3. Inverse probability of treatment weighting IPTW involves weighting each treated individual by the inverse of their propensity score and each untreated individual by the inverse of one minus their propensity score. Like matching, implementing IPTW is directly effected by the measurement error in T since the definition of the weight for each observation relies on an indicator of treatment assignment. With only T ep available in lieu of T , IPTW will be subject to measurement error regardless of how the propensity score estimation was carried out. Note that the use of IPTW can be construed as a further extension of subclassification, with the number of subclasses going to infinity (Stuart, 2010) .
Outcome analyses
We consider outcome analyses that can be expressed via a likelihood function constructed conditional on the implementation stage. For all three implementations we specify
where r is known. For subclassification, the treatment effect is estimated by maximizing the likelihood of the outcome model for each the k subclasses of individuals that have a similar propensity score value. For matching, the treatment effect is estimated by maximizing a weighted likelihood of the outcome model, where the weights are determined based on the matches (Stuart and Green, 2008) . For IPTW, the treatment effect is estimated by maximizing a weighted likelihood of the outcome model, where the weights are determined based on the inverse propensity score (Harder and others, 2010) . Note that fitting this regression model to adjust for X in the outcome stage, in addition to the propensity score adjustment, is not necessary since the propensity score implementation would, in principle adjust for confounding. A gold-standard outcome model with true T cannot be fitted in the main study as T ep is observed in place of T . An outcome model that includes T ep in place of T will not estimate the treatment effect of interest regardless of how the propensity score estimation and implementation are conducted. Therefore, the outcome analyses stage is directly impacted by the misclassified T .
TWO-STEP LIKELIHOOD-BASED ADJUSTMENT
We propose a two-step likelihood-based adjustment that adjusts for both the treatment misclassification in the propensity score estimation and outcome analysis stages. This approach fully adjusts for treatment misclassification when using the subclassification implementation described in Section 3.2.1, but fails to fully adjust with matching and IPTW, as these implementations rely on use of T in a manner that is not reflected in the likelihood.
Assumptions about the measurement error mechanism
The proposed adjustment relies on two common measurement error assumptions; the first is nondifferential measurement error; (Y 0 , Y 1 ) ⊥ ⊥ T ep |T , X. This is equivalent to the surrogacy assumption (T ep is a surrogate for T conditional on X) (Carroll and others, 2006) . The second, that the measurement error models defined in Sections 4.2, 4.3 are transportable from the validation to the main study. Adjusting the propensity score estimation stage relies on a measurement error model,
, while adjusting the outcome analysis stage relies on a measurement error model,
(where h and f are known). We assume both measurement error models are transportable, implying that P(t, x) and P(t ep , x) are also transportable, where the latter can be empirically verified by comparing P(t ep , x) in the two studies. When this fails to hold, a reasonable approach is to assume that one of the two measurement error models is transportable and estimate the other using Bayes' Theorem. This is further discussed in Section 7 and Appendix A of the supplementary materials available at Biostatistics online.
Step 1: adjusting the propensity score model
In this first step our goal is to estimate of the propensity score in the main data ( PS adj ), using the validation data to adjust for the error in T . We define
T can be written as the product of the likelihoods from the main and the validation studies. The likelihood of the main study can be rewritten in terms of γ using the law of total probability, by summing over all possible values of T , as P(
Putting the two parts together, the likelihood function is
Although one could maximize this likelihood jointly to obtain estimates of η and γ this is computationally demanding. Instead, we propose a pesudo-likelihood approach (Buonaccorsi, 2010) , where η is replaced byη obtained using the validation data on N v individuals, and L(γ ,η) is maximized with respect to γ . Detailed derivation of the likelihood assuming the propensity score model is a logit is provided in Appendix B of the supplementary materials available at Biostatistics online.
Step 2: adjusting the outcome model
After adjusting the propensity score estimation and implementing based on PS adj , misclassification of T must be corrected in the outcome model. We develop the proposed approach in the context of subclassification, where observations are classified into K subgroups based on PS adj (see Section 3.2.1) of sizes N mk in the main study and based on PS true of sizes N vk in the validation study. With this strategy, a separate treatment effect is estimated for each of the K subgroups. Denote estimates from subgroup k with
For each of the K subclasses, a procedure analogous to that represented in Expression (4.1) is applied to rewrite the likelihood for β k in the main study by summing over possible values of T , weighted by a measurement-error model. Specifically, we write
Propensity scores with misclassified treatment
Once again, we use a pseudo-likelihood approach, where θ is replaced byθ, which is estimated in the validation data, and L(β k ,θ ) is maximized to obtain estimates of β k . An overall estimateβ is obtained bŷ
. Detailed derivation of the likelihood assuming the outcome model is logit is provided in Appendix B of the Supplementary Materials.
Adjustment under matching and IPTW
We explore the performance of the two-step likelihood-based adjustment using matching and IPTW. The first step of the likelihood adjustment, which estimates PS adj in the main study, remains identical to that used for subclassification (Section 4.2). Estimates of PS adj are then used in conjuncture with T ep in the main study to implement matching or IPTW. The outcome stage is then represented by a weighted likelihood expression, with weights determined by the implementation (Harder and others, 2010) . The second step of the adjustment is then applied to the weighted likelihood.
For full matching, all individuals are matched based on estimated propensity scores, with a variable number of treated and untreated observations in each matched group. Each observation is assigned a weight according to the matching: treated individuals are assigned a weight of 1, and control individuals are assigned a weight proportional to the number of matched treated individuals. For observations in the main study, matches are formed based on T ep using PS adj , and w . For the main study, the analogous w adj are constructed with T ep and PS adj in place of T and PS true , respectively.
In both cases, likelihood-based estimates of β are obtained by maximizing a weighted likelihood expression. For IPTW, the likelihood function for the adjustment is
with w m adji and w m truej replacing w adji and w truej for the matching implementation. θ is replaced byθ which is estimated using the validation data, and L(β,θ ) is maximized with respect to β. Equations 4.3 and 4.2 assume β are the same in the main and validation studies. Under settings in which this assumption unlikely holds, the validation component of the likelihood should be omitted.
SIMULATIONS
We use simulations to evaluate the performance of the proposed adjustment under the three implementations outlined in Section 3.2. We compare the proposed adjustment against treatment effect estimates (1) 3000 and 100 (2) 3000 and 500 (3) 3000 and 1500
Covariate Distribution
obtained using the true treatment assignment in all three stages (gold standard) and using only error-prone treatment assignment in all three stages (no adjustment).
Simulation characteristics
Data are simulated to reflect the setting of a main and validation study, assuming a setting in which the validation study is a random sample of the main study (in Appendix C of the supplementary materials available at Biostatistics online, we consider the setting in which the validation study is not a random sample). We consider confounders X = (1, X 1 , . . . , X 6 ) that include both continuous (X 1 , X 2 , X 3 ) and binary covariates (X 4 , X 5 , X 6 ). [T |X, γ ], [T ep |T , X, η], and [Y |T , X, β] were generated as Bernoulli random variables, with probability of success specified by logistic regression. We consider four scenarios and three sample sizes to reflect moderate or strong associations between X and T in the propensity score model and two measurement error models (Table 1) . For each sample size, each scenario is simulated 500 times. These parameters generate data with sensitivity/specificity between 25 and 50%. Note that data are generated so that covariates X relate to the treatment to simulate confounding. However, when estimating the ATE in simulations, we assume an outcome model with β 2 = 0 (we present results under β 2 = 0 in Appendix D of the supplementary materials available at Biostatistics online), thus relying only on the propensity score to adjust for confounding. A simulation study based on real SEER-Medicare data is presented in Section 5.3. For subclassification we group observations into quartiles of the propensity score ( PS adj ). For matching, we use full matching to obtain weights for each individual as described in Section 3.2.2. For IPTW, weights are calculated as described in Section 3.2.3 and stabilized following Robins and others (2000) , using T for stabilization in the gold standard approach and T ep in the no adjustment and adjustment approaches. Analysis was conducted in R using the MatchIt R-package (Ho and others, 2011) , and code is available on https://github.com/daniellebraun/LikAdjPS.
Simulation results
We present a detailed description of the results from a simulation scenario with a moderate association between T and X, a measurement error model dependent on X, and N m = 3000 and N v = 1500 (Figure 2, Fig. 2 . Bias and MSE of the ATE estimator, under simulation setting with a moderate association between T and X and measurement error dependent of X (Table 1 ). Gold Standard is based on the true treatment assignment. No Adj is based on the error-prone treatment assignment. Two-step Adj is based on the error-prone treatment assignment with the proposed two-step likelihood-based adjustment, adjusting both the propensity score and outcome model. Average sensitivity is 0.46 and average specificity is 0.47. The true treatment effect is −0.19. Table 1 ). In this scenario, the average sensitivity is 0.46 and the average specificity is 0.47. Figure 2 summarizes the effects of measurement error using each method in terms of bias and √ MSE of (the treatment effect in the entire population of both main and validation studies). For this scenario, we also compare the empirical standard error based on 500 replicates to that based on bootstrapping, estimates were similar and not presented here. For reference, a naive analysis fitting an outcome-model without confounding adjustment for X, exhibits substantial bias (bias = −0.32, MSE = 0.32) in the ATE even when using T .
Results for implementation with subclassification
The proposed two-step likelihood-based adjustment performs very well in terms of bias and mean squared error (MSE), with estimates that are much better than in the absence of the adjustment and very close to the gold standard (Figure 2) . Thus, adjusting for measurement error in the propensity score estimation and in the outcome analysis with our likelihoodbased approach can accurately recover estimates of the ATE without knowledge of which observations in the main study are truly treated. Appendix E of the Supplementary Materials available at Biostatistics online shows that subclassifying based on the PS adj does in fact improve covariate balance with respect to the true T , as compared to no adjustment or subclassification based on PS ep .
Results for Implementation with Matching and IPTW
Both matching and IPTW rely on a misclassified treatment indicator in the implementation stage, which is not accommodated in the proposed two-step likelihood-based adjustment. For both of these implementations, the gold standard performs well in terms of bias and MSE, whereas ignoring measurement error (No Adj) increases bias and MSE (Figure 2) . Even though our two-step adjustment does not directly account for error in T in the implementation, the corrected estimator using matching performs well in terms of bias and MSE. In contrast, the inability of the proposed approach to adjust for misclassification in the IPTW implementation has more 704 D. BRAUN AND OTHERS pronounced implications, with substantial bias and MSE that are only slightly smaller than when conducting no measurement error adjustment (Figure 2) . We investigate the relative robustness to the failure to account for treatment misclassification in the matching and IPTW implementations by examining in detail how the use of T vs. T ep impacts the corresponding weights for each procedure.
Matching: For full matching, each observation receives a weight based on a treatment indicator and the matched sets (see Section 4.4). To investigate the implication of using T ep for defining the weights in the main study, we compare the values of w m adj , calculated using T ep and PS adj , to the weights that would be obtained if observations were instead matched based on T and PS adj , which we denote with w m Tadj . Use of w m Tadj would fully account for the measurement error, but these weights require knowledge of T which are only available in the simulated data.
In order to understand which observations have weights most impacted by the use of T ep (vs. T ), we plot histograms of PS adj for T = 0 (blue) and T = 1 (red) observations, shown in the left panel of 
Results for other scenarios
Results from the other scenarios and sample sizes are shown in Appendix E of the supplementary materials available at Biostatistics online. Bias and MSE for estimates of the ATE are similar across the three other scenarios. For smaller sample sizes, performance of the proposed approach suffers when N v is as low as 100, where each subclass has only 25 observations. Results under a setting of no treatment effect are shown in Appendix F of the supplementary materials available at Biostatistics online.
Simulated data analysis using SEER-medicare data
To further validate the proposed method, we use the real validation data for our data analysis (SEERMedicare, described in Section 6) and split the dataset into two parts: a mock validation study (n = 1582) and a mock main study (n = 1530) where we ignore the known value of T . The sensitivity and specificity in the mock validation study are those reported in the introduction. It is important to note that this illustration cannot substitute the primary data analysis, since it addresses a different scientific question by evaluating w adj are weights obtained by weighting individuals based on their adjusted propensity score using the error-prone treatment assignment and w Tadj are weights obtained by weighting individuals based on their adjusted propensity score using the true treatment assignment (Note, a color version of this figure is available in the online version). treatment effect in SEER-Medicare patients, whereas primary interest lies in the entire Medicare Part A population.
Results from this analysis are shown in Table 2a , 95% confidence intervals were obtained by bootstrap. Since the true treatment is known we can compare the ATE based on the gold standard, the error-prone treatment (no adjustment), and our proposed two-step likelihood-based adjustment. For all implementations, the ATE based on the adjustment is closer to the gold standard, motivating the importance of the measurement error adjustment. For example, for subclassification the ATE based on the gold standard is −0.02 95% CI: (−0.07, 0.01), based on the error-prone −0.11 95% CI: (−0.17, −0.04), and based on the adjustment −0.05 95% CI: (−0.09, −0.02). In this setting, the error-prone treatment assignment results in an overestimate of the treatment effect of resection vs. biopsy in SEER-Medicare patients by 8%. For full matching, the estimated ATE based on the gold-standard is more extreme than for subclassification and IPTW, likely due to a few observations with large weights, although the key point remains that the adjusted estimates are closer to the gold standard.
The consistency with which the adjustment produces estimates closer to the gold standard with all three implementations is explained by the observed distribution of PS adj in the SEER-Medicare data. Unlike in Figure 3 , the range of PS adj in this illustration is [0.52 − 0.81], which does not contain observations in the tail ends of the propensity score that were shown to render the analysis most susceptible to values of T = T ep .
COMPARATIVE EFFECTIVENESS OF SURGICAL PROCEDURES
We apply the proposed methods to estimate the effect of tumor resection versus neurosurgical biopsy on mortality within 1 year of diagnosis among Medicare beneficiaries ages 65 and older diagnosed with malignant neoplasm of brain between 1999 and 2007. Medicare Part A claims represent the main study with determination of biopsy versus resection (T ep ) based on ICD9 codes (codes 0111, 0112, 0113, 0114, 0118 for biopsy, and 0123, 0124, 0125, 0139, 0151, 0152, 0153, 0159, 0299 for resection). The validation data come from SEER-Medicare, where surgical treatment is ascertained by medical chart reviews and represents a more accurate measure of T . For SEER-Medicare, biopsy was measured as the procedural code for local excision of tumor, lesion, or mass, excisional biopsy. Resection was measured by three different procedural codes; subtotal resection of tumor, lesion, or mass in brain, partial resection of lobe of brain, and gross total resection of lobe of brain (lobectomy). We take these measures in SEER-Medicare as the gold standard (Cooper and others, 2000; Chawla and others, 2014) . As SEER-Medicare is technically a subset of the Medicare population and individuals cannot be linked between data sources, we limit attention to Medicare Part A observations diagnosed in even years and SEER-Medicare observations diagnosed in odd years in order to prevent individuals from counting twice. Additional restrictions considered, as well as more details on the even/odd year split, are described in Appendix A of the supplementary materials available at Biostatistics online. The final data includes 10 284 Medicare Part A observations and 1582 SEER-Medicare observations. Confounders with at least 2% prevalence in both the main and validation data were selected to be included in the propensity score model (Table 1 of supplementary materials available at Biostatistics online), where comorbidity history is identified from hospitalization records using the hierarchical conditions category method (Pope and others, 2004) . We see that resection rates based on ICD9 codes are higher in SEER-Medicare compared to Medicare Part A (91.9% vs. 60.9%), and 1-year mortality rates are lower in SEER-Medicare compared to Medicare Part A (72.6% vs. 93.5%). Patient characteristics also differ between the two cohorts. Note, the transportability assumptions required for our approach does not require that the two populations be the same, only that the mechanism driving the error in the treatment assignment is the same across the two populations.
We hypothesize that any erroneous or misclassified ICD-9 codes used to identify biopsy versus resection should arise similarly in the Medicare Part A and SEER-Medicare datasets. In other words, we believe that the mechanism driving error in treatment assignment is likely similar in the two populations; that E(T |T ep = t ep , X = x, θ ) is transportable. P(t ep , x) is not the same in the main and validation studies, indicating that the required transportability of both measurement error models (Section 4.1) does not hold. As previously suggested, we assume transportability of one of the measurement error models,
where f is logit, and is estimated in the SEER-Medicare data. We estimate the joint distribution of T ep and X in the main study, and combine the two estimates to derive E(T ep |T = t, X = x) using Bayes' theorem (additional details are summarized in Section 7 and Appendix A of the supplementary materials available at Biostatistics online). Since the validation data (SEER-Medicare) is not assumed to be representative of the population of interest (Medicare Part A), it is used only for the estimation of the measurement-error models, but omitted from the likelihood in Equations 4.1 and 4.2.
Data analysis results
For each propensity score implementation, we compare the estimated ATE in Medicare Part A with those obtained using only T ep (no adjustment), 95% confidence intervals were obtained by bootstrap (Table 2b) . For both evaluations, confounders were not included in the outcome model and we assume propensity score implementations account for all potential confounders. We see that all three implementations perform similarly, with the adjustment yielding more pronounced point estimates (95% confidence intervals) of ATE relative to the analysis with no adjustment: −0.10(−0.11, −0.09) vs. −0.06(−0.07, −0.05) for subclassification; −0.10(−0.11, −0.09) vs. −0.06(−0.06, −0.05) for IPTW, and −0.10(−0.11, −0.08) vs. −0.07(−0.07, −0.05) for matching. An ATE of −0.10 implies that the probability of dying within one year is 10% larger for those who received a biopsy compared to those who had a resection. Thus, compared to no adjustment of the Medicare Part A population, the adjustment for mismeasured treatment indicates that surgery is 3 − 4% more effective for preventing death within 1 year of diagnosis.
Although our interest is in estimating the treatment effect in the entire Medicare Part A population, Table 2b also presents estimates of the ATE in the SEER-Medicare population for comparison. Confining attention to only the SEER-Medicare population and using the true treatment assignment results in smaller ATE estimates (for example, −0.04(−0.07, −0.01) for subclassification, Table 2b ). As SEER-Medicare is not a random sample of Medicare Part A (Table 1 supplementary materials available at Biostatistics online), it is not surprising that the estimates differ across the two populations.
The agreement between results of the adjustment under the three implementations is likely due to the absence of extreme values of PS adj that yield the most susceptibility to misclassified treatment (the range of PS adj is [0.52 − 0.81]). We also performed a sensitivity analysis to gauge sensitivity to the transportability 708 D. BRAUN AND OTHERS assumption, using 100 different values of θ sens in place ofθ estimated from SEER-Medicare. Results provided in Appendix G of the supplementary materials available at Biostatistics online show that the adjustment is sensitive only to large variability in estimates θ .
DISCUSSION
We introduced an innovative two-step likelihood-based approach to estimate the average causal effect in the main study accounting for the error in the treatment assignment. Our approach was developed for propensity score subclassification, where the implementation stage does not directly involve a measure of treatment assignment. Our simulation study shows that the proposed method can reliably correct for misclassified treatment when used with propensity score subclassification. In addition, we have detailed the different ways in which measurement error in the treatment assignment can impact the three stages of estimating causal effects using propensity scores and illustrated the potential for bias in estimates of causal treatment effects. We showed that the method has varying performance when used with the matching and IPTW implementations, with IPTW proving substantially more susceptible to measurement error in T relative to matching.
We show that susceptibility of matching and IPTW to mismeasured T depends heavily on the distribution of estimated adjusted propensity scores. In fact, both matching and IPTW performed similarly to subclassification in the data application, due to the lack of estimated propensity scores in ranges that are most sensitive to values of T ep = T . Thus, looking at the range of PS adj can help guide the choice of propensity score implementation. Extensions along the lines of the multiple imputation approach of Webb-Vargas and others (2015) may prove fruitful for future research to accommodate error in the implementation step.
While not considered here, related work in Braun and others (2016) considers how varying rates of treatment misclassification impact estimation of the propensity scores and treatment effect, considering a wide range of sensitivity and specificity values and indicating that the impact depends on these rates. They found that even under a situation of small measurement error (both specificity and sensitivity are relatively high around 90%) there can be substantial bias in the ATE.
Deriving the asymptotic properties of our proposed estimator is not straightforward. Our overall estimator (i) estimates an adjusted propensity score, (ii) implements using the adjusted propensity score, and (iii) adjusts the outcome model. One could extend work by Buonaccorsi (1996) to binary outcomes to derive the properties of the adjusted propensity score estimator. However, accounting for the uncertainty that propagates through these three stages in order to derive asymptotic properties of the overall estimator, is complex and is subject for future work.
The proposed method relies on the fact that a validation study is available with (T , T ep ). This was the case in the motivating data analysis, but extensions to settings when historical misclassification rates are available instead of validation data may prove fruitful. In addition, the method requires transportability of both E(T ep |T = t, X = x, η), and E(T |T ep = t ep , X = x, θ ), which was suspect in the data application. In this case, we assumed E(T |T ep = t ep , X = x, θ) was transportable, estimated the joint distribution of T ep and X in the main study, and used Bayes' Theorem to estimate E(T ep |T = t, X = x, θ). This highlights the importance of giving careful thought to the transportability assumptions. The approach also assumes nondifferential measurement error (surrogacy). In the context of the brain cancer investigation, we believe it is reasonable to assume that given the true treatment assignment and confounders, the error-prone treatment assignment does not provide any additional information on the 1-year mortality.
While the SEER-Medicare validation data contained the data on the outcome of interest, our approach is motivated by the desire to estimate the ATE in the entire Medicare Part A population. The SEER-Medicare is not a random sample of Medicare Part A, therefore we were not able to estimate the treatment effect directly SEER-Medicare. Additionally, even when the validation study is representative of the main study, one might not be able to estimate the ATE in the validation study directly, under settings in which the sample size of the validation study might be too small or when the validation study does not have outcome information. Our proposed adjustment can be applied under both of these settings.
The results using all three implementations indicated that surgical treatment (versus biopsy) for Medicare PartA brain cancer patients has a more pronounced benefit for 1 year mortality than would be estimated using the error prone ICD9 codes to identify treatment. This analysis assumes that (i) all variables included in X are sufficient to adjust for confounding, (ii) treatment assignment based on SEER-Medicare is the gold standard. However, the notion of surgical treatment in patients with malignant brain tumors is complex. Surgeons' decisions about whether to expand a biopsy procedure into a more extensive resection often occur in the operating room based on a real-time assessment of tumor location. This lends some ambiguity to the distinction between biopsy and resection, which can translate into ambiguities in SEER-Medicare procedural codes. Thus, the treatment assignment we regarded as "true" might not be an absolute goldstandard, which is a limitation of our analysis. Nonetheless, use of these codes does imply more accurate information compared to ICD-9 codes, and represents the best treatment assignment available.
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